gsk201602016k7.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending February 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--


 
 
GlaxoSmithKline plc
                     
Notification of Transactions of Directors, Persons Discharging
Managerial Responsibilities or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) I give details of changes in the notional interests of the following Directors and Persons Discharging Managerial Responsibilities ('PDMR'), who acquired Ordinary Shares and American Depositary Shares (ADSs), at a price of 1380.50 pence per Ordinary Share and $40.28 per ADS, following the re-investment of dividends paid to Shareholders on 14 January 2016, on Ordinary Shares and ADSs held in the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
 
 
 Director/PDMR
 
  Number of Ordinary Shares acquired under the personal
 contribution element of the plan
 
  Number of Ordinary Shares acquired under the matching element
  of the plan 
 
(GSK contribution)
 
 Sir Andrew Witty
 
1,793.426
 
1,793.426
 
 Mr S Dingemans
 
684.427
 
684.427
 
 Mr R G Connor
 
357.433
 
357.433
 
 Mr N Hirons
 
77.446
 
77.446
 
 Mr S A Hussain
 
306.724
 
306.724
 
 Mr D S Redfern
 
383.037
 
383.037
 
 Ms C Thomas 
 
262.846
 
262.846
 
 Mr P C Thomson
 
129.188
 
129.188
 
 Dr P J T Vallance
 
917.547
 
917.547
 
 Ms E Walmsley
 
541.228
 
541.228
 
 
 Director/PDMR
 
 Number of ADSs acquired under the personal contribution element
 of the plan
 
   Number of ADSs acquired  under the matching element of the plan
 
(GSK contribution)
 
 Dr M M Slaoui
 
687.416
 
687.416
 
 Mr D E Troy
 
290.867
 
290.867
 
GlaxoSmithKline plc ('GSK') was advised of these allocations on 28 January 2016.
 
V A Whyte
Company Secretary
 
1 February 2016

 
 

 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: February 01, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc